drugset / Trial / NCT05205486

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

NCT05205486

Phase 1 Completed 12 enrolled B. Braun Medical SA
NaSingle-groupOpen-labelPrevention

Summary

This study is designed to evaluate the pharmacokinetics (PK) of a single 3 gm dose of cefazolin from a DUPLEX container, in adult subjects (weighing \>/= 120 kg) scheduled for surgery. Cefazolin will be administered as a 30-minute intravenous (IV) infusion, per cefazolin Package Insert. Five PK samples per subject will be obtained up to 8 hours after dosing. These data will then be assessed by the validated Cefazolin PK Model to verify there are no significant PK changes within this study population.

Timeline

Start
2022-04-05
Primary completion
2023-07-13
Completion
2023-07-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefazolin Small molecule 3 g Intravenous

Indications